Emerging platinum(0) nanotherapeutics for efficient cancer therapy

J Control Release. 2022 Dec:352:276-287. doi: 10.1016/j.jconrel.2022.10.021. Epub 2022 Oct 26.

Abstract

Platinum (Pt)-based chemotherapy has been necessary for clinical cancer treatment. However, traditional bivalent drugs are hindered by poor physicochemical properties, severe toxic side effects, and drug resistance. Currently, elemental Pt(0) nanotherapeutics (NTs) have emerged to tackle the dilemma. The inherent acid-responsiveness of Pt(0) NTs could help to improve tumor selectivity and alleviate toxic effects. Moreover, the metal nature of Pt facilitates the great combination of Pt(0) NTs with photothermal and photodynamic therapy and imaging-guided diagnosis. Based on recent important researches, this review provides an updated introduction to Pt(0) NTs. First, the challenges of traditional Pt-based chemotherapy have been outlined. Then, Pt(0) NTs with multiple applications of tumor theranostics have been overviewed. Furthermore, the combinations of Pt(0) NTs with other therapeutical modalities are introduced. Last but not least, we envision the possible challenges and prospects associated with Pt(0) NTs.

Keywords: Acid-responsiveness; Metal nature; Pt(0) nanotherapeutics; Therapeutical modalities; Tumor theranostics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Neoplasms* / drug therapy
  • Photochemotherapy*
  • Platinum / chemistry
  • Platinum / therapeutic use

Substances

  • Platinum